Nalin C W Goonesekere1, Wyatt Andersen2, Alex Smith2, Xiaosheng Wang3. 1. Department of Chemistry and Biochemistry, University of Northern Iowa, 1227 W. 27th Street, Cedar Falls, IA, 50613-0423, USA. nalin.goonesekere@uni.edu. 2. Department of Chemistry and Biochemistry, University of Northern Iowa, 1227 W. 27th Street, Cedar Falls, IA, 50613-0423, USA. 3. Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. xiaosheng.wang@cpu.edu.cn.
Abstract
PURPOSE: The lack of specific symptoms at early tumor stages, together with a high biological aggressiveness of the tumor contribute to the high mortality rate for pancreatic cancer (PC), which has a 5-year survival rate of about 7%. Recent failures of targeted therapies inhibiting kinase activity in clinical trials have highlighted the need for new approaches towards combating this deadly disease. METHODS: In this study, we have identified genes that are significantly downregulated in PC, through a meta-analysis of large number of microarray datasets. We have used qRT-PCR to confirm the downregulation of selected genes in a panel of PC cell lines. RESULTS: This study has yielded several novel candidate tumor-suppressor genes (TSGs) including GNMT, CEL, PLA2G1B and SERPINI2. We highlight the role of GNMT, a methyl transferase associated with the methylation potential of the cell, and CEL, a lipase, as potential therapeutic targets. We have uncovered genetic links to risk factors associated with PC such as smoking and obesity. Genes important for patient survival and prognosis are also discussed, and we confirm the dysregulation of metabolic pathways previously observed in PC. CONCLUSIONS: While many of the genes downregulated in our dataset are associated with protein products normally produced by the pancreas for excretion, we have uncovered some genes whose downregulation appear to play a more causal role in PC. These genes will assist in providing a better understanding of the disease etiology of PC, and in the search for new therapeutic targets and biomarkers.
PURPOSE: The lack of specific symptoms at early tumor stages, together with a high biological aggressiveness of the tumor contribute to the high mortality rate for pancreatic cancer (PC), which has a 5-year survival rate of about 7%. Recent failures of targeted therapies inhibiting kinase activity in clinical trials have highlighted the need for new approaches towards combating this deadly disease. METHODS: In this study, we have identified genes that are significantly downregulated in PC, through a meta-analysis of large number of microarray datasets. We have used qRT-PCR to confirm the downregulation of selected genes in a panel of PC cell lines. RESULTS: This study has yielded several novel candidate tumor-suppressor genes (TSGs) including GNMT, CEL, PLA2G1B and SERPINI2. We highlight the role of GNMT, a methyl transferase associated with the methylation potential of the cell, and CEL, a lipase, as potential therapeutic targets. We have uncovered genetic links to risk factors associated with PC such as smoking and obesity. Genes important for patient survival and prognosis are also discussed, and we confirm the dysregulation of metabolic pathways previously observed in PC. CONCLUSIONS: While many of the genes downregulated in our dataset are associated with protein products normally produced by the pancreas for excretion, we have uncovered some genes whose downregulation appear to play a more causal role in PC. These genes will assist in providing a better understanding of the disease etiology of PC, and in the search for new therapeutic targets and biomarkers.
Entities:
Keywords:
DNA microarray; Pancreatic cancer; Therapeutic targets; Tumor-suppressor genes
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Clare Abbenhardt; Elizabeth M Poole; Richard J Kulmacz; Liren Xiao; Karen Curtin; Rachel L Galbraith; David Duggan; Li Hsu; Karen W Makar; Bette J Caan; Lisel Koepl; Robert W Owen; Dominique Scherer; Christopher S Carlson; John D Potter; Martha L Slattery; Cornelia M Ulrich Journal: Int J Mol Epidemiol Genet Date: 2013-09-12
Authors: Geng Zhang; Peijun He; Hanson Tan; Anuradha Budhu; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Anirban Maitra; Nader Hanna; H Richard Alexander; S Perwez Hussain Journal: Clin Cancer Res Date: 2013-08-05 Impact factor: 12.531
Authors: Kelly R Pekala; Xidi Ma; Peter A Kropp; Christine P Petersen; Courtney W Hudgens; Christine H Chung; Chanjuan Shi; Nipun B Merchant; Anirban Maitra; Anna L Means; Maureen A Gannon Journal: Lab Invest Date: 2014-03-17 Impact factor: 5.662
Authors: Khalid A Hajj; Jilian R Melamed; Namit Chaudhary; Nicholas G Lamson; Rebecca L Ball; Saigopalakrishna S Yerneni; Kathryn A Whitehead Journal: Nano Lett Date: 2020-06-09 Impact factor: 11.189